We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

208 hedge funds and large institutions have $2.85B invested in Ariad Pharmaceuticals Inc in 2013 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 83 increasing their positions, 62 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 21

34% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 62

6% more capital invested

Capital invested by funds: $2.69B → $2.85B (+$164M)

5% more funds holding

Funds holding: 198208 (+10)

43% less call options, than puts

Call options by funds: $21.9M | Put options by funds: $38.3M

60% less funds holding in top 10

Funds holding in top 10: 52 (-3)

Holders
208
Holders Change
+10
Holders Change %
+5.05%
% of All Funds
6.74%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.06%
New
34
Increased
83
Reduced
62
Closed
21
Calls
$21.9M
Puts
$38.3M
Net Calls
-$16.4M
Net Calls Change
-$16.5M
Name Holding Trade Value Shares
Change
Change in
Stake
TA
76
Teton Advisors
New York
$4.27M +$1.1M +56,507 +32%
Citadel Advisors
77
Citadel Advisors
Florida
$4.15M -$1.85M -95,268 -30%
NTCOC
78
Northern Trust Company of Connecticut
Connecticut
$4.04M +$77.1K +3,973 +2%
HCM
79
Highbridge Capital Management
New York
$3.76M +$3.3M +170,217 +497%
Nomura Holdings
80
Nomura Holdings
Japan
$3.71M +$3.6M +185,585 +1,225%
PC
81
PointState Capital
New York
$3.68M +$3.88M +200,000 New
Barclays
82
Barclays
United Kingdom
$3.58M +$2.06M +106,152 +114%
Fidelity International
83
Fidelity International
Bermuda
$3.47M +$2.26M +116,310 +161%
ARTA
84
A.R.T. Advisors
New York
$3.37M +$3.56M +183,377 New
Lord, Abbett & Co
85
Lord, Abbett & Co
New Jersey
$3.23M -$264K -13,599 -7%
Bank of Montreal
86
Bank of Montreal
Ontario, Canada
$3.17M -$4.31K -222 -0.1%
U
87
UBS
Switzerland
$3.12M -$1.62M -83,282 -33%
BIM
88
BlackRock Investment Management
Delaware
$3.11M +$1.79M +92,357 +121%
Group One Trading
89
Group One Trading
Illinois
$3.09M +$2.31M +118,986 +244%
RhumbLine Advisers
90
RhumbLine Advisers
Massachusetts
$3.08M -$72.8K -3,748 -2%
PAMU
91
Pictet Asset Management (UK)
United Kingdom
$3.08M +$198K +10,200 +6%
Swiss National Bank
92
Swiss National Bank
Switzerland
$2.9M -$159K -8,200 -5%
FAM
93
Fred Alger Management
New York
$2.89M +$3.05M +157,270 New
BNP Paribas Asset Management
94
BNP Paribas Asset Management
France
$2.81M +$2.97M +152,733 New
SONJCPFA
95
State of New Jersey Common Pension Fund A
New Jersey
$2.76M
DCM
96
DAFNA Capital Management
California
$2.74M -$821K -42,300 -22%
Zurich Cantonal Bank
97
Zurich Cantonal Bank
Switzerland
$2.67M -$874K -45,000 -24%
State of Wisconsin Investment Board
98
State of Wisconsin Investment Board
Wisconsin
$2.5M -$204K -10,530 -7%
NFA
99
Nationwide Fund Advisors
Ohio
$2.4M +$87.4K +4,500 +4%
WMSA
100
Weiss Multi-Strategy Advisers
New York
$2.02M -$194K -10,000 -8%

ARIA Hedge Fund Activity: Q3 2013 in Review

208 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q3 2013, worth a combined $2.85B — up 6.1% from $2.69B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new ARIA positions and 21 closed out — a net gain of 13 holders — while 83 added to existing stakes and 62 trimmed.

The largest buyer was Franklin Resources, adding an estimated $64.5M. The largest seller was Artisan Partners, cutting an estimated $135M.

  • 208 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q3 2013, up from 198 in Q2 2013.
  • Funds reported $2.85B of Ariad Pharmaceuticals Inc stock for Q3 2013, up 6.1% quarter-over-quarter.
  • 34 funds opened new Ariad Pharmaceuticals Inc positions in Q3 2013 and 21 closed out, a net change of +13 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q3 2013 was Franklin Resources, an estimated $64.5M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q3 2013 was Artisan Partners, an estimated $135M sold.

Based on aggregated 13F filings for Q3 2013.